GlassScriptPhysician profile
Warren S Line
NPI 1205918588
$3,041.31
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $267 · 2021: $653 · 2022: $784 · 2023: $814 · 2024: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $677.22 | 2019-2024 | |
| Optinose US, INC. | $511.34 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $486.87 | 2019-2023 | Dupixent |
| Glaxosmithkline, LLC. | $274.64 | 2021-2024 | Nucala |
| Novartis Pharmaceuticals Corporation | $193.19 | 2021-2023 | |
| Acclarent, INC | $176.79 | 2019-2021 | |
| Aerin Medical INC. | $161.36 | 2019-2021 | |
| Stryker Corporation | $151.07 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $124.30 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $83.64 | 2020-2023 | Fasenra |
| Genentech USA, INC. | $44.36 | 2023 | Xolair |
| Alk-Abello, INC | $42.86 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Phadia US INC. | $41.38 | 2023 | Immunocap |
| Hikma Pharmaceuticals USA | $37.12 | 2023 | Ryaltris |
| Merck Sharp & Dohme LLC | $21.88 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Line listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.